-
Mashup Score: 0
Are patients enrolled in Medicare Advantage more or less likely to be prescribed high-cost drugs for cancer treatment compared with traditional Medicare? A new study investigated.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status - 9 day(s) ago
Final data from the phase III TALAPRO-2 study show a significant improvement in overall survival in men with metastatic prostate cancer treated with a combination of talazoparib and enzalutamide vs en…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
The TALAPRO-2 study shows that talazoparib + enzalutamide improves overall survival in metastatic castration-resistant prostate cancer, regardless of HRR gene status (45.1 vs 31.1 months). A significant advancement in treatment options. https://t.co/rB5GSIjMKA #ASCO2025 https://t.co/UuCm7TGYgy
-
-
Mashup Score: 2
A recent ASCO survey measuring the impact of professional well-being and satisfaction on career plans among oncologists in the United States revealed a higher rate of burnout compared with that observ…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Over 59% of oncologists are experiencing burnout, a significant increase from 45% a decade ago. Work-life balance and support solutions are critical to improve job satisfaction and retention in the field. #Oncology #PhysicianBurnout https://t.co/DTTPMvLzX6 https://t.co/ZfHWTh4u9Q
-
-
Mashup Score: 5
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed a significant benefit with the addition of pertuz…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
The Japanese phase III PRECIOUS study reveals that pertuzumab retreatment in combination with trastuzumab & chemotherapy significantly improves overall survival in patients with HER2-positive, locally advanced/metastatic breast cancer. #HER2Positive https://t.co/ZteW8kXEL5 https://t.co/NTMfBTuKx1
-
-
Mashup Score: 9Survival Outcomes in Patients With ERBB2-Positive Metastatic Breast Cancer With CNS Involvement - 13 day(s) ago
Patients with ERBB2-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial metastases have been found to experience longer overall survival but remain at h…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Study from Memorial Sloan Kettering reveals that patients with ERBB2-positive metastatic breast cancer and CNS metastases have longer overall survival but remain at high risk for CNS-related death. Aggressive treatments may be needed. #BreastCancer #ERBB2 https://t.co/8yIpY0pW2N https://t.co/nKbqCad3M1
-
-
Mashup Score: 4Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer - 16 day(s) ago
The results from the phase III FIRE-4 randomized clinical trial showed that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type-mutated metastatic colorectal cancer. These findi…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
The FIRE-4 trial shows liquid biopsy's accuracy in detecting RAS/BRAF mutations in metastatic colorectal cancer, aiding in treatment decisions. https://t.co/4PESnJHsS8 #ColorectalCancer #LiquidBiopsy https://t.co/rVM7sGyJsq
-
-
Mashup Score: 5Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations - 17 day(s) ago
As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan in patients with advanced or metastatic non–sm…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
The TROPION-Lung05 trial finds that datopotamab deruxtecan shows encouraging activity in advanced/metastatic NSCLC with actionable genomic alterations after prior targeted therapy and chemotherapy. #LungCancer #OncologyResearch https://t.co/5YTxD1S5U1 https://t.co/Biskq1jaON
-
-
Mashup Score: 8Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results - 18 day(s) ago
Platinum-based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, defined as lasting at least 3 months.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
A global analysis finds chemotherapy-induced neuropathy affects over 40% of patients, with the highest rates in those treated with platinum-based agents and taxanes. #Oncology #Neuropathy https://t.co/1MH135rAum https://t.co/ah1M99cHmX
-
-
Mashup Score: 4Thermal Ablation vs Surgical Resection of Small Resectable Colorectal Liver Metastases - 19 day(s) ago
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation was noninferior to surgical resection in terms of …
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
The COLLISION trial finds thermal ablation is noninferior to surgical resection for small resectable colorectal liver metastases, offering similar survival outcomes with a better safety profile. #Oncology #LiverCancer https://t.co/kCew3Sxbwg https://t.co/Tjsj39qvUY
-
-
Mashup Score: 7TACE and Durvalumab/Bevacizumab in Unresectable HCC - 20 day(s) ago
“Durvalumab plus bevacizumab plus [transarterial chemoembolization (TACE)] has the potential to set a new standard of care” in this patient population, according to researchers who conducted the EMERA…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
The EMERALD-1 trial finds that adding durvalumab/bevacizumab to TACE improves progression-free survival in unresectable hepatocellular carcinoma. Could this be a new standard of care? #LiverCancer #OncologyResearch https://t.co/XrN6jdmTR8 https://t.co/BOKLvdnIfg
-
Medicare Advantage patients generally receive less expensive cancer drugs than those on traditional Medicare, especially for colorectal cancer. However, high-cost treatments are common for NSCLC. #Medicare #CancerCare https://t.co/jSLxivQxL9 https://t.co/HBO7ilk5ti